Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

Jonathan Massey, Darren Plant, Kimme Hyrich, Ann W Morgan, Anthony G Wilson, Athina Spiliopoulou, Marco Colombo, Paul McKeigue, John Isaacs, Heather Cordell, Costantino Pitzalis, Anne Barton, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), MATURA Consortium

Research output: Contribution to journalArticlepeer-review


Rheumatoid arthritis (RA) is characterised by chronic synovial joint inflammation. Treatment has been revolutionised by tumour necrosis factor alpha inhibitors (TNFi) but each available drug shows a significant non-response rate. We conducted a genome-wide association study of 1,752 UK RA TNFi-treated patients to identify predictors of change in the Disease Activity Score 28 (DAS28) and subcomponents over 3-6 months. The rs7195994 variant at the FTO gene locus was associated with infliximab response when looking at a change in the swollen joint count (SJC28) subcomponent (p = 9.74 x 10-9). Capture Hi-C data show chromatin interactions in GM12878 cells between rs2540767, in high linkage disequilibrium with rs7195994 (R2=0.9) and IRX3, a neighbouring gene of FTO. IRX3 encodes a transcription factor involved in adipocyte remodelling and is regarded as the obesity gene at the FTO locus. Importantly, the rs7195994 association remained significantly associated following adjustment for BMI. In addition, using capture Hi-C data we showed interactions between TNFi-response associated variants and 16 RA susceptibility variants.
Original languageEnglish
JournalThe Pharmacogenomics Journal
Publication statusPublished - 31 Aug 2018


Dive into the research topics of 'Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this